
Antibody screening is a crucial process used in the development of new drugs, vaccines, and diagnostic tests. Antibodies are proteins that the immune system produces in response to foreign substances such as viruses, bacteria, or cancer cells. Antibody screening involves identifying and selecting antibodies that bind specifically to a target antigen, which is a molecule on the surface of a foreign substance.
Antibody screening is typically carried out using techniques such as enzyme-linked immunosorbent assay (ELISA), flow cytometry, and phage display. In ELISA, the target antigen is immobilized onto a solid surface, and a sample containing antibodies is added. If the antibodies bind to the antigen, they can be detected using a secondary antibody that recognizes and binds to the primary antibody. Flow cytometry involves labeling cells or particles with fluorescent markers and passing them through a flow cytometer, which measures the intensity of the fluorescence. Antibodies that bind to the target antigen can be detected by the increase in fluorescence intensity. Phage display is a method in which antibodies are displayed on the surface of bacteriophages, and phages that bind to the target antigen are selected through multiple rounds of screening.
Antibody screening is critical in drug development, as it allows researchers to identify antibodies that can selectively target disease-causing substances without affecting healthy cells. This specificity is essential to minimize side effects and maximize therapeutic efficacy. In vaccine development, antibody screening helps identify the most effective antigens to include in the vaccine, which can stimulate the immune system to produce specific antibodies. Antibody screening is also used in diagnostic tests, where it can detect the presence of specific antibodies in patient samples, which can indicate the presence of a particular disease.
In conclusion, antibody screening is a vital process in the development of new drugs, vaccines, and diagnostic tests. It enables researchers to identify and select antibodies that can specifically target a particular antigen, which is essential for the development of effective treatments and diagnostics.
Two popular topics discussed at the 2026 BIO International Convention were devel……
AI is changing antibody discovery, but model performance depends on the quality ……
Antibody discovery has become increasingly sequence-rich. Display technologies, ……
Biointron, a leading contract research organization specializing in antibody dis……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



